Simulations Plus (NASDAQ:SLP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Simulations Plus (NASDAQ:SLP) posted its quarterly earnings results on Wednesday. The technology company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02, Briefing.com reports. The business had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

Shares of Simulations Plus stock traded down $0.28 on Friday, reaching $30.68. The stock had a trading volume of 276,597 shares, compared to its average volume of 130,076. The business’s 50-day moving average price is $33.20 and its two-hundred day moving average price is $40.76. Simulations Plus has a fifty-two week low of $29.37 and a fifty-two week high of $51.22. The stock has a market cap of $613.91 million, a P/E ratio of 64.50 and a beta of 0.69.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SLP. BTIG Research decreased their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday. Craig Hallum reiterated a “buy” rating and issued a $56.00 target price on shares of Simulations Plus in a research note on Wednesday, July 3rd. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Thursday. KeyCorp began coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. Finally, JMP Securities began coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus price target of $54.50.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the director now directly owns 3,501,592 shares in the company, valued at approximately $123,186,006.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 60,750 shares of company stock worth $2,145,055. 20.90% of the stock is owned by insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.